Condition
Malignant Glioma (WHO Grade III or IV)
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Terminated2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06666712Phase 1Recruiting
Chronic CED of TPT for Recurrent Malignant Glioma
NCT01989052Phase 1TerminatedPrimary
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
NCT01954030Phase 1TerminatedPrimary
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Showing all 3 trials